scispace - formally typeset
M

Matthew J. Grainge

Researcher at University of Nottingham

Publications -  161
Citations -  12236

Matthew J. Grainge is an academic researcher from University of Nottingham. The author has contributed to research in topics: Population & Cohort study. The author has an hindex of 47, co-authored 147 publications receiving 10081 citations. Previous affiliations of Matthew J. Grainge include University of Leicester & Nottingham University Hospitals NHS Trust.

Papers
More filters
Journal ArticleDOI

Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK

TL;DR: In this article , a prognostic model was developed and validated that uses information collected during routine clinical care and may be used to risk stratify the frequency of monitoring blood test during long term methotrexate treatment.
Journal ArticleDOI

The smoking, nicotine and pregnancy (SNAP) trial: main results

TL;DR: The SNAP trial was designed to test the hypothesis that the addition of NRT transdermal patches for up to 8 weeks, to conventional behavioural advice, reduces the rate of smoking between the agreed quit date and delivery.
Journal ArticleDOI

Predicting Need for Escalation of Care or Death From Repeated Daily Clinical Observations and Laboratory Results in Patients With Severe Acute Respiratory Syndrome Coronavirus 2

TL;DR: A bespoke daily SARS-CoV-2 escalation risk prediction score can predict need for clinical escalation better than a generic early warning score or a single estimation of risk calculated at admission.
Posted ContentDOI

Risk of death during the 2020 UK COVID-19 epidemic among people with rare autoimmune diseases compared to the general population. Preliminary results from the RECORDER project.

TL;DR: The risk of all-cause death is more prominently raised during COVID-19 among people with RAIRD than among the general population, and better guidance about shielding, access to healthcare and vaccine priorities for people with rare diseases is needed.